BioSpace News Archive

Terns Pharmaceuticals, Inc. announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis programs within the Company’s portfolio were accepted for presentation at The International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in June.

Alkermes plc announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 2:40 p.m. PT.

Aquestive Therapeutics, Inc. announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor and certain of the Company’s executives, to purchase 8,850,000 shares of its common stock and warrants to purchase up to an aggregate of 8,850,000 shares of common stock at a purchase price per share of $0.96 for the institutional investor and $1.09 for the Company’s executives for gross proceeds of approximately $8.5 million.

Neurocrine Biosciences, Inc. will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA.

Baxter International Inc., a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28, 2022 at 7:30 a.m. Central Time.

CureVac N.V. announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

Sciwind Biosciences Co., Ltd. announced that two abstracts have been accepted for poster presentations at The International Liver CongressTM 2022, the Annual Meeting of the European Association for the Studies of the Liver taking place June 22-26 in London, United Kingdom.

Vertex Pharmaceuticals Incorporated announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022.